← Leaderboards
Roya Khosravi-Far
Beth Israel Deaconess Medical Center
$10,044,273
Attributed
$10,044,273
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,044,273 · 8
By mechanism
R01$6,943,194 · 3
R44$1,414,853 · 1
R42$755,999 · 1
K01$500,490 · 1
R43$329,737 · 1
R55$100,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Rebecca Luckett$1,026,248
- Daniel K Sodickson$15,585,280
Others in their field
Top investigators on “Apoptosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$49,205,802
- Jay A Nelson · Oregon Health & Science University$45,942,124
- John C Reed · University Of Texas Md Anderson Can Ctr$34,437,189
- John A Tainer · Scripps Research Institute$30,637,655
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$28,872,594
- John D Minna · University Of Texas Sw Med Ctr/Dallas$27,317,167
Research focus
ApoptosisCellsApoptoticProteinsMediatingResistanceTumorMolecularPlayRegulationSignal PathwaySignal TransductionMemberCell TransformationCytokineFamilyLeukemiaGenesResponsePreventReceptorMouse ModelCessation Of LifeDesign
Grant awards (26)
Point of Care Detection of HPV and P16 in Saliva$1,414,853
R44 · FY2025 · DE · contact PI
Point of care detection of HPV in saliva$329,737
R43 · FY2023 · DE · contact PI
A multimodal platform for Oral screening of COVID-19$500,000
R42 · FY2022 · DE · contact PI
A multimodal platform for Oral screening of COVID-19$255,999
R42 · FY2021 · DE · contact PI
Novel Strategies for Treatment of Myeloproliferative Disorders$342,168
R01 · FY2012 · CA · contact PI
Novel Strategies for Treatment of Myeloproliferative Disorders$368,268
R01 · FY2011 · CA · contact PI
Tumor Selective Apoptosis by TRAIL$632,013
R01 · FY2010 · HL · contact PI
Novel Strategies for Treatment of Myeloproliferative Disorders$352,750
R01 · FY2010 · CA · contact PI
Tumor Selective Apoptosis by TRAIL$646,990
R01 · FY2009 · HL · contact PI
Tumor Selective Apoptosis by TRAIL$393,508
R01 · FY2009 · HL · contact PI
Novel Strategies for Treatment of Myeloproliferative Disorders$352,750
R01 · FY2009 · CA · contact PI
Oncogene-Induced Evasion from Apoptosis$318,352
R01 · FY2009 · CA · contact PI
Tumor Selective Apoptosis by TRAIL$266,055
R01 · FY2009 · HL · contact PI
Tumor Selective Apoptosis by TRAIL$393,508
R01 · FY2008 · HL · contact PI
Novel Strategies for Treatment of Myeloproliferative Disorders$352,750
R01 · FY2008 · CA · contact PI
Oncogene-Induced Evasion from Apoptosis$318,352
R01 · FY2008 · CA · contact PI
Tumor Selective Apoptosis by TRAIL$393,508
R01 · FY2007 · HL · contact PI
Oncogene-Induced Evasion from Apoptosis$318,352
R01 · FY2007 · CA · contact PI
Tumor Selective Apoptosis by TRAIL$405,260
R01 · FY2006 · HL · contact PI
Oncogene-Induced Evasion from Apoptosis$327,860
R01 · FY2006 · CA · contact PI
Tumor Selective Apoptosis by TRAIL$425,000
R01 · FY2005 · HL
Oncogene-Induced Evasion from Apoptosis$335,750
R01 · FY2005 · CA
DISSECTING THE FAS SIGNALING PATHWAYS$152,830
K01 · FY2002 · CA
DISSECTING THE FAS SIGNALING PATHWAYS$174,030
K01 · FY2001 · CA
TRAIL induced apoptotic pathways$100,000
R55 · FY2001 · CA
DISSECTING THE FAS SIGNALING PATHWAYS$173,630
K01 · FY2000 · CA